Search
Close this search box.

Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology by Alain Moreau, PhD, Montreal Collaboration

From the desk of Dr. Alain Moreau, PhD
Director of the Collaborative Research Center 
at the CHU Sainte-Justine/Université de Montréal

#TripleGivingTuesday Research Update

Montréal ME/CFS Research Center Paper
Published in Scientific Reports

On behalf of Open Medicine Foundation (OMF), I am pleased to share that an article authored by my research team at the OMF Funded ME/CFS Collaborative Research Center (CRC) at Université de Montréal has been published online by Scientific Reports!

You might remember in my last update from the Research Center at Montréal, I shared a brief update about this study, entitled “Profile of circulating microRNAs in myalgic encephalomyelitis and their relation to symptom severity, and disease pathophysiology,” and our groundbreaking discovery and validation of different microRNAs associated with ME/CFS.

MicroRNAs can represent potential indicators for diseases such as ME/CFS, and changes in microRNA expression could indicate cellular dysfunction and degeneration. Using a test to induce mild-but-reproducible Post Exertional Malaise (PEM), our team has so far uncovered and validated 11 different microRNAs associated with ME/CFS that are capable of differentiating ME/CFS patients from healthy patients — wit 90 percent accuracy! 

This post-exertional stress challenge provoking PEM in ME/CFS patients has helped us gain unprecedented insight into the pathophysiology of ME/CFS. Based on the 11 different microRNA signatures discovered in ME/CFS, machine learning algorithms have also led to the classification of ME/CFS patients into four clusters associated with symptom severity.

These exciting results could lead to the development of a new, non-invasive diagnostic test for ME/CFS, a prognostic tool used to predict future cases, and identification of effective treatment options.

Read the full paper

Thank you to all who have supported our work. It is through your donations, small and large, and your belief in our mission to end ME/CFS, that we have been given the opportunity to advance research with confidence and urgency.

Join us in this outstanding effort to uncover answers as we boldly move closer to the discovery of a diagnostic test, treatments, and a cure for ME/CFS.

Join us in this outstanding effort to uncover answers as we boldly move closer to the discovery of a diagnostic test, treatments, and a cure for ME/CFS.

All donations to OMF will be TRIPLED from now until December 1, giving you the exciting opportunity to TRIPLE your support of this innovative research.

It’s with your support that we’re leading critical research and delivering hope for millions. 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669